Newswise — Lawrenceville, NJ, USA—February 6, 2018—ISPOR, the professional society for health economics and outcomes research (HEOR), announced today the release of its “Top 10 HEOR Trends” list that identifies the most influential topics in the field of health economics and outcomes research for 2018.
In today’s rapidly changing, global, healthcare environment, interest in the field of HEOR has grown exponentially with governments and other payers seeking to provide the best possible health outcomes at affordable costs. As HEOR continues to grow in importance, playing an ever greater role in helping to inform healthcare decisions, ISPOR continues to lead by examining topics and trends that will have the most influence on its membership and the healthcare community in the coming year. This is the inaugural compilation of ISPOR’s Top 10 HEOR Trends.
The highly debated issue of drug pricing topped the list of HEOR trends. Innovative and curative therapies came in a close second, perhaps not surprisingly, as balancing incentives for research with pricing of these novel, breakthrough therapies is integrally connected. Accelerated drug approvals and the evidentiary needs they require for reimbursement rounded out the top 3 trends of 2018. The complete list of “Top 10 HEOR Trends” is available for download here.
“Part of achieving the ISPOR mission includes dissemination of information that helps the healthcare community and media understand and appreciate the importance of health economics and outcomes research in decision making. We are pleased to release ISPOR’s first ‘Top 10 HEOR Trends’ list,” noted ISPOR CEO and Executive Director, Nancy S. Berg.